Generic Name: cobimetinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Cotellic is a kinase inhibitor approved to treat inoperable or metastatic melanoma with BRAF V600E or V600K mutations in combination with Zelboraf (vemurafenib).
Cotellic is a targeted therapy that interferes with the activity of MEK (mitogen-activated extracellular signal-regulated kinase) proteins that play a role in cell growth. It is more effective when combined with the BRAF inhibitor Zelboraf. Certain BRAF gene mutations, including V600E and V600K, promote tumor growth.
A clinical trial showed that Cotellic plus Zelboraf delayed progression of melanoma in people with BRAF V600 mutations more than Zelboraf alone. Cotellic was first approved in 2015.
Cotellic is a once-daily pill that can be taken with or without food.
Common adverse reactions include diarrhea, nausea, vomiting, fever, photosensitivity reactions and elevated liver enzymes. More serious adverse events may include new malignancies, heavy bleeding, heart problems, severe skin reactions, eye problems, liver toxicity and muscle damage. Cotellic can cause fetal harm if used during pregnancy.
For More Info: https://www.cotellic.com/
Patient Assistance Program Info: https://www.genentech-access.com/hcp/brands/cotellic/find-patient-assistance.html
Last Reviewed: August 9, 2020